Earlier this week, news of a safety issue with Ariad Pharmaceuticals' (NASDAQ: ARIA) leukemia drug Iclusig caused the drugmaker's shares to plunge more than 65%. Today, the stock took another 20% tumble after the FDA announced that it is investigating the safety problems associated with the medication. In the following video, health-care analysts Max Macaluso and David Williamson discuss the details behind both of Ariad's drops this week.
S&P 500
6,008.68
+1.2%
+$69.38
DJI
42,845.57
+1.2%
+$525.83
NASDAQ
19,526.92
+1.2%
+$228.47
Bitcoin
104,235.00
-1.3%
-1,376.57
AAPL
$204.41
+1.9%
+$3.78
AMZN
$212.55
+2.2%
+$4.64
GOOG
$173.61
+2.2%
+$3.80
META
$698.70
+2.1%
+$14.08
MSFT
$472.09
+0.9%
+$4.41
NVDA
$142.01
+1.4%
+$2.02
TSLA
$291.85
+2.5%
+$7.15
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Shares of Ariad plunged 70% earlier this week -- why did the shares drop another 20% today?
Alison Southwick has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.